Orgenesis stock gains 5.45 percent on October 2

Published on 10/04/2026 at 12:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Orgenesis stock sat 42 percent below its USD 1.00 52-week high on October 2. The OTC Expert Market listing and 100-share volume add trading context.

ORGS, US68619K3032, Illustration mit AI erstellt.

Orgenesis stock (ISIN US68619K3032) was last at USD 0.58 on the OTC Expert Market on October 2, 2026 at 4:00 p.m. ET, up 5.45 percent from USD 0.55. Zonebourse identifies the company under ticker ORGS and the same ISIN.

OTC status changes the read

StockTitan reported on June 2, 2026, that Orgenesis trades on the OTC Expert Market after its Nasdaq listing ended. That venue places greater weight on liquidity and transaction size when investors assess a daily percentage move.

The October 2 quotation came with volume of 100 shares. Orgenesis had a market capitalization of USD 5.7 million, so the 5.45 percent daily gain represents a market move in a very small quoted equity.

Stock stays below yearly high

At USD 0.58, ORGS stood 42 percent below its 52-week high of USD 1.00 on October 2, 2026. The price was also 42 percent above the session low of USD 0.58 only in the sense that the session range began and ended at the same quoted low, making the daily high of USD 0.91 the more relevant intraday reference.

The company describes its POCare Platform as a way to simplify the development and scale-up of advanced therapies. On its investor-relations page, Orgenesis says it works with biotech companies, hospitals, academic institutions and research organizations to commercialize point-of-care therapies.

Liquidity remains the key variable

For investors, the combination of a USD 0.58 quote, a USD 5.7 million market capitalization and 100 shares traded makes the reported percentage change more informative as a snapshot than as a broad measure of demand. The 42 percent gap to the USD 1.00 yearly high also leaves the stock well below its recent peak.